We are offering grants for researchers investigating novel drug targets in the fields of the indications listed below to promote innovative therapeutic ideas from basic research into novel drugs.
We provide financial support to test your hypothesis, start or extend your present research activities.
Focus on oncogenic signaling.
Focus on novel treatment options for endometriosis (incl. adenomyosis uteri/endometriosis interna), uterine fibroids (uterine leiomyoma) and polycystic ovary syndrome (PCOS).
Focus on Atrial Fibrillation, Chronic Heart Failure, Peripheral Artery Disease, Cardioprotective mechanisms.
Focus on Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, COPD- Frequent Exacerbators, Chronic Cough, Pulmonary Hypertension.
Focus on Hypertensive Nephropathy, Diabetic Kidney Disease, Acute Kidney Injury, Chronic Allograft Nephropathy, Polycystic Kidney Disease
Focus on Acute Respiratory Distress Syndrome, DIC, SIRS, Acute Coronary Syndrome, Stroke Prevention in Atrial Fibrillation, Venous Thrombosis, Hemophilia A
What is a Target?
There are two types of grants, that will be allocated by Bayer depending on the target, the scientific data provided and the maturity of the proposal.
Support grants (€ 5,000 - €10,000)*
For druggable targets that are at a very early stage of discovery.
Focus grants (€ 10,000 - €125,000)*
For more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug discovery process.
* The size of the individual grant will depend on the target specifics and the phase of development and validation.
Within Bayer´s Compound Collection, we may have chemical probes to support your target validation efforts. Please indicate in your application which requirements potential tool compounds should fulfill.
Bayer‘s R&D focusses on identifying and developing novel drugs (including antibodies and antibody derivatives) for treating diseases with high unmet medical need. We are committed to innovation and to translating initial ideas from basic research into novel drugs. Complementing our internal efforts, we are dedicated to fostering collaborations with academic groups, start-up and biotech companies.
We can offer access to different technologies to assist in your target validation, e.g. gene expression profiling or other state-of-the-art research technologies. Please detail your research interest for the technology platforms in the online submission.
Successful projects supported by the grant may lead to further collaboration.
Grant applications can only be submitted via the online submission platform ScholarOne™.
As first step, you’ll have to create an account in the Grants4Targets Submission central.
You’ll need to submit an abstract describing your idea and target, its characteristics and a separate description of its therapeutic potential.
Please note that only non-confidential information should be provided.
The information provided will be evaluated by Bayer scientific experts. The decision on amount of funding is dependent on the specific target and research plan proposed.
Successful applicants will be notified by Bayer and will receive further instructions concerning the grant. A Bayer caretaker will be in contact with you during the grant period.
To submit, you will be redirected to ScholarOne™ online submission platform. All the information provided has to be non-confidential to allow a first evaluation of the proposal.
Describe your idea and target, its characteristics (indication and treatment paradigm, the target´s druggability, and patent status).
Please indicate in the abstract if any particular data can only be disclosed under a Confidential Disclosure Agreement (CDA). In case your application is considered for further evaluation, we may contact you to discuss a CDA.
To assist in the grant allocation, the proposal should include a detailed description of the target proposed, the phase of discovery, and further research plans.
This information can be provided as PDF-Documents which can be attached to the application.
These supplements are to assist the scientific reviewers. The publications attached do not necessarily have to originate from yourself / your research group. Please attach the most relevant publications describing the target and its functional relevance for the indicated disease.
Bayer offers a unique incubator for startup life-science companies whose drug targets and technologies align with Bayer.s interests.
Bayer is promoting the exploration of new indications by offering grants and further financial support.
Bayer offers financial support to evaluate your antibody or derivate and to promote its exploration for a potential new drug development.